IN8bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INAB research report →
About the company
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies.
- CEO
- Tai-Wei
- IPO
- 2021
- Employees
- 18
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $13.98M
- P/E
- -0.38
- P/S
- 0.00
- P/B
- 0.27
- EV/EBITDA
- 0.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -96.39%
- ROIC
- -76.21%
- Revenue
- $0 · 0.00%
- Net Income
- $-19,440,000 · 36.13%
- EPS
- $-4.44 · -678.95%
- Op Income
- $-19,861,000
- FCF YoY
- 47.59%
- 52W High
- $2.73
- 52W Low
- $1.17
- 50D MA
- $1.53
- 200D MA
- $1.80
- Beta
- 0.19
- Avg Volume
- 57.55K
Get TickerSpark's AI analysis on INAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 27, 26 | FAIRBAIRN EMILY | other | 724,637 |
| May 9, 26 | Ho William Tai-Wei | other | 154,500 |
| May 9, 26 | Greenwood Luba | other | 22,000 |
| May 9, 26 | Lamb Lawrence | other | 54,000 |
| May 9, 26 | FAIRBAIRN EMILY | other | 22,000 |
| May 9, 26 | McCall Patrick | other | 56,250 |
| May 9, 26 | Rochlin Kate | other | 60,000 |
| May 9, 26 | Epperly Corinne | other | 22,000 |
| May 9, 26 | Brandt Peter C. | other | 22,000 |
| May 9, 26 | Graff Jeremy R. | other | 22,000 |
Our INAB coverage
Recent articles, reports, and earnings notes.
No research on INAB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INAB report →Similar companies
Peers in the same neighborhood.